Noticias y Actividades de Ironwood Pharmaceuticals
Presencia
Ironwood Pharmaceuticals desarrolla y comercializa medicamentos con receta para enfermedades gastrointestinales y raras. Sus productos y servicios apoyan a pacientes, profesionales de la salud y mercados de atención especializada en Estados Unidos.
Visión general de los productos y servicios de Ironwood Pharmaceuticals:
- Medicamentos con receta
- Salud digestiva
- Enfermedades raras
- Desarrollo de fármacos
Ingresos: ~$393 million
Empleados: 300
Sede: Boston, Estados Unidos
Ironwood Pharmaceuticals es una de las ...
Ironwood Pharmaceuticals es una empresa que cotiza bajo el símbolo de cotización IRWD (US).
Ejecutivos
Ver el organigrama con sus 25 ejecutivos principales
Biografías más buscadas en Ironwood Pharmaceuticals
- Thomas McCourt, Chief Executive Officer and Director
- Mark Currie, Director
- Julie McHugh, Chairman of the Board
Recientes movimientos de ejecutivos en Ironwood Pharmaceuticals
- Michael Shetzline que es Senior Vice President, Chief Medical Officer and Head of Research and Development, pasará a ser Advisor el 20 de jul.. de 2026 (noticia publicada el 16 de julio de 2026).
- Jeffrey Silber se incorporará a la empresa como Chief Medical Officer el 20 de jul.. de 2026 (noticia publicada el 15 de julio de 2026).
- Ronald Silver que ha sido Senior Vice President, Corporate Controller and Chief Accounting officer, pasa a ser Senior Vice President, Corporate Controller, Chief Accounting officer and Interim Chief Financial Officer (noticia publicada el 15 de mayo de 2026).
Haga clic aquí para ver otros movimientos en Ironwood Pharmaceuticals
Crear su alerta
para seguir los movimientos de los ejecutivos en Ironwood Pharmaceuticals.
Farmacia
Ironwood Pharmaceuticals tiene 1.919 competidores entre los que se incluyen Sanofi (Francia), Moderna (Estados Unidos) y Eli Lilly (Estados Unidos).
Popular M&A news in Farmacia
- Samsung Biologics has announced the acquisition of PolyPeptide Group (publicado el 22 de julio de 2026).
- Ipsen ha Memo Therapeutics adquirido (publicado el 22 de julio de 2026).
- Eli Lilly has announced the acquisition of AtaiBeckley (publicado el 17 de julio de 2026).
Otros contactos sugeridos en el sector Farmacia
Noticias
Últimos comunicados de prensa de Ironwood Pharmaceuticals
- Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients
- FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)
- Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
- Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance
- Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)
- Ironwood Pharmaceuticals to Host First Quarter 2026 Investor Update Call
- Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026
- Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference
- Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook
- Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Investor Update Call
- View more press releases Close
Redes sociales sobre Ironwood Pharmaceuticals
- Ironwood Pharmaceuticals en Wikipedia, Google News y Yahoo Finance
- Ironwood Pharmaceuticals en LinkedIn, Twitter y YouTube
